GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (NAS:PALI) » Definitions » Gross-Profit-to-Asset %

Palisade Bio (Palisade Bio) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Palisade Bio's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. Palisade Bio's average Total Assets over the quarter that ended in Mar. 2024 was $13.35 Mil. Therefore, Palisade Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.


Palisade Bio Gross-Profit-to-Asset % Historical Data

The historical data trend for Palisade Bio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio Gross-Profit-to-Asset % Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
- - - 1.68

Palisade Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.45 - - - -

Competitive Comparison of Palisade Bio's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Palisade Bio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palisade Bio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Palisade Bio's Gross-Profit-to-Asset % falls into.



Palisade Bio Gross-Profit-to-Asset % Calculation

Palisade Bio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.25/( (15.763+14.052)/ 2 )
=0.25/14.9075
=1.68 %

Palisade Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (14.052+12.652)/ 2 )
=0/13.352
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Palisade Bio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Palisade Bio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Palisade Bio (Palisade Bio) Business Description

Traded in Other Exchanges
Address
5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.
Executives
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
John David Finley officer: Chief Financial Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Robert J. Trenschel director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Mitchell Lawrence Jones officer: Chief Medical Officer 70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907
Robert Curtis Mcrae officer: Chief Operating Officer 675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075
Thomas Hallam director, officer: Chief Executive Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Michael John Dawson officer: Chief Medical Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Yuma Regional Medical Center 10 percent owner 2400 S AVENUE A, YUMA AZ 85364
Stephanie Diaz director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
David J Mazzo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Binxian Wei director P.O. BOX 2231, LIVINGSTON NJ 07039
Kenneth C Carter director, officer: Executive Chairman 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Cristina Csimma director 14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142

Palisade Bio (Palisade Bio) Headlines